Z-350, a novel compound with α1-adrenoceptor antagonistic and steroid 5α-reductase inhibitory actions: Pharmacological properties in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 3, 1999, Pages 1013-1018

  Fukuta, Yoshihisa ^a   Fukuda, Youichi ^a   Higashino, Raita ^a   Yoshida, Kenji ^a   Ogishima, Masayuki ^a   Tamaki, Hajime ^a   Takei, Mineo ^a  

^a ZERIA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 (4 (1 (4 METHYL PHENYL) 3 [4 (2 METHOXYPHENYL)PIPERAZINE 1 YL]PROPOXY)BENZOYL)INDOLE 1 YL]BUTYRIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PHENYLEPHRINE; PRAZOSIN; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLADDER NECK STENOSIS; DOSE RESPONSE; ENZYME INHIBITION; GROWTH INHIBITION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT; URETHRA PRESSURE;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; DIHYDROTESTOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DUODENUM; ENZYME INHIBITORS; GROWTH SUBSTANCES; HYPOTENSION, ORTHOSTATIC; INDOLES; MALE; ORGAN SIZE; PHENYLEPHRINE; PIPERAZINES; PROSTATE; PROSTATIC HYPERPLASIA; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE; URETHRA;

EID: 0032812925     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, Lehtonen T and Tveter K (1995) Can finasteride reverse the progress of benign prostatic hyperplasia? A two year placebo-controlled study. Urology 46:631-637.
2. Bartsch W, Sponer G, Strein K, Böhm E and Hooper RG (1967) Evaluation of the risk for drug-induced postural hypotension in an experimental model: Investigations with carvedilol, prazosin, labetarol, and guanethdine. J Cardiovasc Pharmacol 10 (Suppl 11):S49-S51.
3. Baulieu EE, Lasnitzki I and Robel P (1968) Metabolism of testosterone and action of metabolites on prostate glands grown in organ culture. Nature (Lond) 219:1155-1156.
4. Caine M, Pfau A and Perlberg S (1976) The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 48:255-263.
5. 1-adrenoceptor subtypes present in the human prostate. Life Sci 21:1595-1605.
6. 1-adrenoceptor classification. Br J Pharmacol 121:1127-1135.
7. 1c subtype. Mol Pharmacol 45:703-708.
8. 1-adrenoceptor antagonistic and steroid 5α-reductase inhibitory actions. Naunyn-Schmiedeberg's Arch Pharmacol 359:433-436.
9. Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T, Izumi T and Abiko Y (1982) Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 128:836-839.
10. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B and Ng J (1992) The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327:1185-1191.
11. 1-adrenoceptors: Consensus update. Pharmacol Rev 47:267-270.
12. Hieble JP and Ruffolo RR Jr (1996) The use of α-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: An overview. Pharmacol Res 33:145-160.
13. Ibrahim MM, Tarazi RC and Dustan HP (1975) Orthostatic hypotension. Mechanisms and management. Am Heart J 90:513-520.
14. Imperato-McGinley J, Guerrero L, Gautier T and Peterson RE (1974) Steroid 5α-reductase deficiency in man: An inherited form of male pseudohermaphroditism. Science (Wash DC) 186:1213-1215.
15. Kawabe K (1995) Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Br J Urol 76(Suppl 1):63-67.
16. Khoury AF and Kaplan NM (1991) α-Blocker therapy of hypertension: An unfulfilled promise. JAMA 266:394-398.
17. Kitada S and Kumazawa J (1987) Pharmacological characteristics of smooth muscle in benign prostatic hyperplasia and normal prostatic tissue. J Urol 138:158-160.
18. 1-adrenoceptor antagonist in the lower urinary tract. Br J Pharmacol 109:1282-1289.
19. Leonardi A, Hieble JP, Guarneri L, Naselsky DP, Poggesi E, Sironi G, Sulpizio AC and Testa R (1997) Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): Role of the alpha-1L adrenoceptor in tissue selectivity, part I. J Pharmacol Exp Ther 281:1272-1283.
20. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P and Padley RJ (1996) The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335:533-539.
21. Liang T, Cascieri MA, Cheung AH, Reynolds GF and Rasmusson GH (1985) Species differences in prostatic steroid 5α-reductases of rat, dog, and human. Endocrinology 117:571-579.
22. 1c-) adrenoceptor subtype. Br J Pharmacol 115:781-786.
23. Martin DJ, Lluel P, Guillot E, Coste A, Jammes D and Angel I (1997) Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther 282:228-235.
24. Martin DJ, Lluel P, Pouyet T, Rauehi-Desanti C and Angel I (1998) Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations. Life Sci 63:169-176.
25. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM and Waldstreicher J (1998) The effect of finasteride on the risks of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338:557-567.
26. Mooradian AD, Morley JE and Korenman SG (1987) Biological actions of androgens. Endocrine Rev 8:1-28.
27. 1-adrenoceptor subtypes in the human prostate: Functional and binding studies. Br J Urol 74:572-578.
28. Okada H, Kawaida N, Ogawa T, Arakawa S, Matsumoto O, Kamidono S and The Kobe University YM617 Study Group (1996) Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. Scand J Urol Nephrol 30:379-385.
29. Page EB, Hickam JB, Sieker HO, McIntoch HD and Pryor WW (1955) Reflex venomotor activity in normal persons and in patients with postural hypotension. Circulation 11:262-270.
30. 1 adrenergic receptor subtypes in human prostate. J Urol 150:546-551.
31. Siiteri PK and Wilson JD (1970) Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest 49:1737-1745.
32. Stoner E (1992) The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol 147:1298-1302.
33. Taguchi K, Saitoh M, Sato S, Asano M and Michel MC (1997) Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther 280:1-5.
34. 1-blocker-induced orthostatic hypotension. Jpn J Pharmacol 77:61-70.
35. Testa R, Guarneri L, Angerico P, Poggesi E, Taddei G, Sironi G, Colombo D, Sulpizio AC, Naselsky DP, Hieble JP and Leonardi A (1997) Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): Role of the alpha-1L adrenoceptor in tissue selectivity, part II. J Pharmacol Exp Ther 281: 1284-1293.
36. 1-antagonist selective for the lower urinary tract: In vivo studies. Neurourol Urodyn 13:471-473.
37. Wasson JH (1998) Finasteride to prevent morbidity from benign prostatic hyperplasia. N Engl J Med 338:612-613.
38. Yamada S, Ashizawa N, Ushijima H, Nakayama K, Hayashi E and Honda K (1987) Alpha-1 adrenoceptors in human prostate: Characterization and alteration in benign prostatic hypertrophy. J Pharmacol Exp Ther 242:326-330.
39. 1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia. Life Sci 62:1585-1589.